Contact Details and References

Aegerion Logo

Any queries or requests for hard copies of the educational materials should be directed to Aegerion Pharmaceuticals.

Marketing authorisation holder:

Aegerion Pharmaceuticals B.V.

Atrium Building

8th Floor

Strawinskylaan 3127

1077 ZX Amsterdam

The Netherlands

 

Medical Information: Tel: 00800 2343 7466, E-mail: medinfo.emea@aegerion.com

 

References

1. Brown RJ, Araujo-Vilar D, Cheung PT, et al. The diagnosis and management of lipodystrophy syndromes: a multi-society practice guideline. J Clin Endocrinol Metab 2016;101:4500–11.

2. Rodriguez AJ, Mastronardi CA, Paz-Filho GJ. New advances in the treatment of generalized lipodystrophy: role of metreleptin. Ther Clin Risk Manag 2015;11:1391–400.

3. Gupta N, Asi N, Farah W, et al. Clinical features and management of non-HIV related lipodystrophy in children: a systematic review. J Clin Endocrinol Metab 2017;102:363–74.

4. Mantzoros CS, Magkos F, Brinkoetter M, et al. Leptin in human physiology and pathophysiology. Am J Physiol Endocrinol Metab 2011;301:E567–84.

5. Chan JL, Oral EA. Clinical classification and treatment of congenital and acquired lipodystrophy. Endocr Pract 2010;16:310–23.

6. Aegerion Pharmaceuticals. Myalepta Summary of Product Characteristics.

Suspected adverse reactions and adverse events should be reported.

Reporting forms and information can be found on the MHRA Yellow Card reporting site or yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse reactions should also be reported to Aegerion by calling 00800 23437466 or e-mail: medinfo.emea@aegerion.com